245 related articles for article (PubMed ID: 33054848)
1. The prognostic value of the lymph node ratio for local advanced gastric cancer patients with intensity-modulated radiation therapy and concurrent chemotherapy after radical gastrectomy in China.
Yang Y; Ma Y; Xiang X; Xing P; Wu Y; Zhang L; Tian Y
Radiat Oncol; 2020 Oct; 15(1):237. PubMed ID: 33054848
[TBL] [Abstract][Full Text] [Related]
2. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
3. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
4. Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and a D2 node dissection for gastric adenocarcinoma.
Leong CN; Chung HT; Lee KM; Shakespeare TP; Mukherjee RK; Wong LC; Lu JJ; Tey J; Lim R; So JB; Back MF
Cancer J; 2008; 14(4):269-75. PubMed ID: 18677137
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection.
Wang X; Shen Y; Zhu H; Zhao Y; Li Z; Qiu M; Li Q; Gou H; Yang Y; Cao D; Liu J; Yi C; Liao Z; Luo D; Bi F; Xu F
Gastric Cancer; 2016 Jan; 19(1):245-54. PubMed ID: 25609451
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of lymph node ratio for local advanced gastric cancer patients with adjuvant chemoradiotherapy after D2 gastrectomy.
Hu M; Zhang S; Yang X; Shen Y; Li Z; Zhao Y; Xu F; Jiang D; Wang X; Wang Y
Medicine (Baltimore); 2018 Nov; 97(44):e13079. PubMed ID: 30383693
[TBL] [Abstract][Full Text] [Related]
7. Concurrent definitive chemoradiation incorporating intensity-modulated radiotherapy followed by adjuvant chemotherapy in high risk locally advanced cervical squamous cancer: a phase II study.
Zhang GY; Zhang R; Bai P; Li SM; Zhang YY; Chen YR; Huang MN; Wu LY
BMC Cancer; 2022 Dec; 22(1):1331. PubMed ID: 36539745
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
Kong L; Zhang YW; Hu CS; Guo Y
Chin J Cancer; 2010 May; 29(5):551-5. PubMed ID: 20426907
[TBL] [Abstract][Full Text] [Related]
9. S-1 chemotherapy and intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with node-positive gastric cancer: a phase I/II study.
Wang X; Zhao DB; Yang L; Chi Y; Tang Y; Li N; Wang SL; Song YW; Liu YP; Liu WY; Ren H; Zhang T; Wang JY; Chen XS; Fang H; Wang WH; Li YX; Jin J
Br J Cancer; 2018 Feb; 118(3):338-343. PubMed ID: 29235569
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes and Prognostic Factors in Gastric Carcinoma Patients with Curative Surgery Followed by Adjuvant Treatment: Real-World Scenario.
Kapoor R; Dracham CB; G Y S; Khosla D; Dey T; Elangovan A; Madan R; Yadav BS; Kumar N
J Gastrointest Cancer; 2021 Jun; 52(2):616-624. PubMed ID: 32535755
[TBL] [Abstract][Full Text] [Related]
11. Image-guided intensity-modulated radiotherapy for patients with locally advanced gastric cancer: a clinical feasibility study.
Badakhshi H; Gruen A; Graf R; Boehmer D; Budach V
Gastric Cancer; 2014; 17(3):537-41. PubMed ID: 24122094
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemoradiation in gastric cancer: long-term outcomes and prognostic factors from a single institution.
Bruixola G; Segura Á; Díaz-Beveridge R; Caballero J; Bennis MH; Palomar L; Giménez A; Mingol F; García-Mora C; Aparicio J
Tumori; 2015; 101(5):517-23. PubMed ID: 26045120
[TBL] [Abstract][Full Text] [Related]
13. Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer.
Hwang JE; Kim H; Shim HJ; Bae WK; Hwang EC; Jeong O; Ryu SY; Park YK; Cho SH; Chung IJ
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2157-2166. PubMed ID: 31273512
[TBL] [Abstract][Full Text] [Related]
14. Intensity modulated radiotherapy (IMRT) combined with concurrent but not adjuvant chemotherapy in primary nasopharyngeal cancer - a retrospective single center analysis.
Saleh-Ebrahimi L; Zwicker F; Muenter MW; Bischof M; Lindel K; Debus J; Huber PE; Roeder F
Radiat Oncol; 2013 Jan; 8():20. PubMed ID: 23347410
[TBL] [Abstract][Full Text] [Related]
15. Survival outcomes and patterns of failure after D2 dissection and adjuvant chemoradiotherapy for locally advanced gastric cancer: a retrospective study.
Yang W; Hu R; Li GC; Zhou ML; Wang Y; Shen LJ; Liang LP; Zhang Z
Br J Radiol; 2018 Sep; 91(1089):20170594. PubMed ID: 29927628
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy.
Han L; Lin SJ; Pan JJ; Chen CB; Zhang Y; Zhang XC; Liao XY; Chen QS
Chin J Cancer; 2010 Feb; 29(2):145-50. PubMed ID: 20109341
[TBL] [Abstract][Full Text] [Related]
17. Intraoperative radiotherapy combined with adjuvant chemoradiotherapy for locally advanced gastric adenocarcinoma.
Fu S; Lu JJ; Zhang Q; Yang Z; Peng L; Xiong F
Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1488-94. PubMed ID: 18538489
[TBL] [Abstract][Full Text] [Related]
18. Lymph Node Burden as a Predictive Factor for Selective Chemoradiotherapy in Patients With Locally Advanced Gastric Cancer After a D2 Dissection: A Retrospective Study.
Li Q; Li G; Palmer JD; Zhang Z
Am J Clin Oncol; 2017 Aug; 40(4):375-380. PubMed ID: 25503428
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
Cats A; Jansen EPM; van Grieken NCT; Sikorska K; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; Boot H; Trip AK; Swellengrebel HAM; van Laarhoven HWM; Putter H; van Sandick JW; van Berge Henegouwen MI; Hartgrink HH; van Tinteren H; van de Velde CJH; Verheij M;
Lancet Oncol; 2018 May; 19(5):616-628. PubMed ID: 29650363
[TBL] [Abstract][Full Text] [Related]
20. Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma.
Cohen DJ; Newman E; Iqbal S; Chang RY; Potmesil M; Ryan T; Donahue B; Chandra A; Liu M; Utate M; Hiotis S; Pachter LH; Hochster H; Muggia F
Ann Surg Oncol; 2012 Feb; 19(2):478-85. PubMed ID: 21769462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
